Clincosm LogoSign in Get a demo

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01009944
Collaborator
University of Utah (Other)
0
Enrollment
1
Location
1
Arm
146.5
Actual Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

Condition or Disease Intervention/Treatment Phase
  • Drug: Lisinopril, Atenolol
 N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Actual Study Start Date :
Jan 1, 2007
Actual Primary Completion Date :
Mar 19, 2019
Actual Study Completion Date :
Mar 19, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Lisinopril, Atenolol

Drug: Lisinopril, Atenolol
once a day for 14 weeks
Other Names:
  • Tenormin (Atenolol)
  • Prinivil, Zestril (Lisinopril)

    		•

    Outcome Measures

    Primary Outcome Measures

    1. One type of blood pressure medication will better treat individuals with certain genetic backgrounds. [16 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male and female hypertensive participants who were previously studied in SCOR program.
    Exclusion Criteria:

    • Diabetes

    • Taking other medications beside thyroid or estrogen supplements.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Brigham and Women's Hospital Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Brigham and Women's Hospital
    • University of Utah

    Investigators

    • Principal Investigator: Gordon H. Williams, MD, Brigham and Women's Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Gordon H. Williams, MD, Chief, Cardiovascular Endocrinology Section, Brigham and Women's Hospital
    ClinicalTrials.gov Identifier:
    NCT01009944
    Other Study ID Numbers:
    • 2007p002290
    First Posted:
    Nov 9, 2009
    Last Update Posted:
    Apr 9, 2021
    Last Verified:
    Apr 1, 2021
    Keywords provided by Gordon H. Williams, MD, Chief, Cardiovascular Endocrinology Section, Brigham and Women's Hospital
    High blood pressure
    Additional relevant MeSH terms:
    Hypertension
    Atenolol
    Lisinopril

    Study Results

    No Results Posted as of Apr 9, 2021